ReviewProstaglandins & other lipid mediators
Eicosanoid profiling in colon cancer: emergence of a pattern.
Review in Prostaglandins & other lipid mediators. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms.Prostaglandins & other lipid mediators · 2024Review
- Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis.Cancer prevention research (Philadelphia, Pa.) · 2022Article
- Lipidomic Signatures for Colorectal Cancer Diagnosis and Progression Using UPLC-QTOF-ESIBiomolecules · 2021Article
- Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer.Frontiers in pharmacology · 2020Review
- Elevated AA/EPA Ratio Represents an Inflammatory Biomarker in Tumor Tissue of Metastatic Colorectal Cancer Patients.International journal of molecular sciences · 2019Article
- The Anti-inflammatory Effect of Personalized Omega-3 Fatty Acid Dosing for Reducing Prostaglandin ECancer prevention research (Philadelphia, Pa.) · 2017Article
- ALOX15 as a suppressor of inflammation and cancer: Lost in the link.Prostaglandins & other lipid mediators · 2017Review
- Effects of fish oil supplementation on prostaglandins in normal and tumor colon tissue: modulation by the lipogenic phenotype of colon tumors.The Journal of nutritional biochemistry · 2017Article
- Eicosanoid pathway in colorectal cancer: Recent updates.World journal of gastroenterology · 2015Review
- The role of 15-LOX-1 in colitis and colitis-associated colorectal cancer.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Review
- Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer.Clinical epigenetics · 2015Article
- Increased eicosanoid levels in the Sugen/chronic hypoxia model of severe pulmonary hypertension.PloS one · 2015Article
- Dietary polyunsaturated fatty acids and inflammation: the role of phospholipid biosynthesis.International journal of molecular sciences · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Oxidative metabolism of polyunsaturated fatty acids has been linked to tumorigenesis in general and colonic tumorigenesis in particular. Earlier studies showed that cyclooxygenase-2 (COX-2) and 15-lipoxygenase-1 (15-LOX-1) have opposing impacts on colonic tumorigenesis: COX-2 promotes while 15-LOX-1 inhibits colonic tumorigenesis. Advances in liquid chromatography/mass spectrometry have allowed for measurement of various products of oxidative metabolism in a single colonic biopsy specimen. Studies of LOX products in preclinical models and in patients with familial adenomatous polyposis and sporadic colorectal tumorigenesis indicate that LOX pathways are shifted during colonic tumorigenesis and that the main shift is downregulation of 15-LOX-1. This shift occurs during the polyp formation stage and thus offers the opportunity to modulate tumorigenesis early by correcting 15-LOX-1 downregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.